相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers
Mohamed E. Salem et al.
JCO PRECISION ONCOLOGY (2022)
Pixelwise H-score: A novel digital image analysis-based metric to quantify membrane biomarker expression from immunohistochemistry images
Sripad Ram et al.
PLOS ONE (2021)
The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy
David M. Briere et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Acquired Resistance to KRASG12C Inhibition in Cancer
M. M. Awad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Mouse lung automated segmentation tool for quantifying lung tumors after micro-computed tomography
Mary Katherine Montgomery et al.
PLOS ONE (2021)
The KRAS(G12C) Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
Jill Hallin et al.
CANCER DISCOVERY (2020)
Discovery of a Covalent Inhibitor of KRASG12C (AMG 510) for the Treatment of Solid Tumors
Brian A. Lanman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer
Jay B. Fell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism
Gerta Hoxhaj et al.
NATURE REVIEWS CANCER (2020)
Characteristics and Outcomes of Patients With Metastatic KRAS-Mutant Lung Adenocarcinomas: The Lung Cancer Mutation Consortium Experience
Badi El Osta et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Targeting the untargetable KRAS in cancer therapy
Pingyu Liu et al.
ACTA PHARMACEUTICA SINICA B (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
The ERK and JNK pathways in the regulation of metabolic reprogramming
Salvatore Papa et al.
ONCOGENE (2019)
Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer
Shuai Li et al.
CLINICAL CANCER RESEARCH (2018)
Imaging Cancer Metabolism: Underlying Biology and Emerging Strategies
Austin R. Pantel et al.
JOURNAL OF NUCLEAR MEDICINE (2018)
KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma
Ernest Nadal et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Targeting pathways downstream of KRAS in lung adenocarcinoma
Zehua Zhu et al.
PHARMACOGENOMICS (2014)
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Jonathan M. Ostrem et al.
NATURE (2013)
Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
Nathan T. Ihle et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
18F-FDG PET/CT Imaging Detects Therapy Efficacy of Anti-EMMPRIN Antibody and Gemcitabine in Orthotopic Pancreatic Tumor Xenografts
Nemil Shah et al.
MOLECULAR IMAGING AND BIOLOGY (2012)
Metabolic Positron Emission Tomography Imaging in Cancer Detection and Therapy Response
Aizhi Zhu et al.
SEMINARS IN ONCOLOGY (2011)
Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma
Katerina Politi et al.
DISEASE MODELS & MECHANISMS (2010)
Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer
Trudy G. Oliver et al.
GENES & DEVELOPMENT (2010)
The differential effects of mutant p53 alleles on advanced murine lung cancer
EL Jackson et al.
CANCER RESEARCH (2005)
Clinical role of FDG PET in evaluation of cancer patients
L Kostakoglu et al.
RADIOGRAPHICS (2003)
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
EL Jackson et al.
GENES & DEVELOPMENT (2001)
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice
L Johnson et al.
NATURE (2001)
分享论文
